Literature DB >> 17438154

Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension.

Fangwen Rao1, Gen Wen, Jiaur R Gayen, Madhusudan Das, Sucheta M Vaingankar, Brinda K Rana, Manjula Mahata, Brian P Kennedy, Rany M Salem, Mats Stridsberg, Kenneth Abel, Douglas W Smith, Eleazar Eskin, Nicholas J Schork, Bruce A Hamilton, Michael G Ziegler, Sushil K Mahata, Daniel T O'Connor.   

Abstract

BACKGROUND: Chromogranin A, coreleased with catecholamines by exocytosis, is cleaved to the catecholamine release-inhibitory fragment catestatin. We identified a natural nonsynonymous variant of catestatin, Gly364Ser, that alters human autonomic function and blood pressure. METHODS AND
RESULTS: Gly364Ser heterozygotes and controls underwent physiological and biochemical phenotyping, including catecholamine production, chromogranin A precursor, and its catestatin product. Case-control studies replicated effects of the gene on blood pressure in the population. Gly364Ser displayed diminished inhibition of catecholamine secretion from cultured neurons. Gly/Ser heterozygotes displayed increased baroreceptor slope during upward deflections (by approximately 47%) and downward deflections (by approximately 44%), increased cardiac parasympathetic index (by approximately 2.4-fold), and decreased cardiac sympathetic index (by approximately 26%). Renal norepinephrine excretion was diminished by approximately 26% and epinephrine excretion by approximately 34% in Gly/Ser heterozygotes. The coalescent dated emergence of the variant to approximately 70,000 years ago. Gly364Ser was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter haplotypes did not predict autonomic phenotypes. The 364Ser variant was associated with lower diastolic blood pressure in 2 independent/confirmatory groups of patients with hypertension; genotype groups differed by approximately 5 to 6 mm Hg, and the polymorphism accounted for approximately 1.8% of population diastolic blood pressure variance, although a significant gene-by-sex interaction existed, with an enhanced effect in men.
CONCLUSIONS: The catestatin Gly364Ser variant causes profound changes in human autonomic activity, both parasympathetic and sympathetic, and seems to reduce risk of developing hypertension, especially in men. A model for catestatin action in the baroreceptor center of the nucleus of the tractus solitarius accounts for these actions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438154     DOI: 10.1161/CIRCULATIONAHA.106.628859

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene.

Authors:  Jiaur R Gayen; Kuixing Zhang; Satish P RamachandraRao; Manjula Mahata; Yuqing Chen; Hyung-Suk Kim; Robert K Naviaux; Kumar Sharma; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2010-08-20

Review 3.  Genotype and vascular phenotype linked by catecholamine systems.

Authors:  David S Goldstein
Journal:  Circulation       Date:  2008-01-29       Impact factor: 29.690

Review 4.  Chromogranin A as a crucial factor in the sorting of peptide hormones to secretory granules.

Authors:  Salah Elias; Charlène Delestre; Maite Courel; Youssef Anouar; Maite Montero-Hadjadje
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

5.  Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension.

Authors:  Kuixing Zhang; Fangwen Rao; Lei Wang; Brinda K Rana; Sajalendu Ghosh; Manjula Mahata; Rany M Salem; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Bamidele Tayo; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

Review 6.  Hereditary determinants of human hypertension: strategies in the setting of genetic complexity.

Authors:  Pei-an Betty Shih; Daniel T O'Connor
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

7.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

Authors:  Nilima Biswas; Sucheta M Vaingankar; Manjula Mahata; Madhusudan Das; Jiaur R Gayen; Laurent Taupenot; Justin W Torpey; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

8.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

9.  Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure.

Authors:  Yuqing Chen; Gen Wen; Fangwen Rao; Kuixing Zhang; Lei Wang; Juan L Rodriguez-Flores; Amber P Sanchez; Manjula Mahata; Laurent Taupenot; Ping Sun; Sushil K Mahata; Bamidele Tayo; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-01       Impact factor: 4.844

10.  Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification.

Authors:  Ryan S Friese; Jiaur R Gayen; Nitish R Mahapatra; Geert W Schmid-Schönbein; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-01       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.